S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
18.55
+1.87
+11.21%
TGTX · TG Therapeutics, Inc.
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
TG Therapeutics Inc (TGTX)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$53.22
-1.31
(-2.41%)
● At close: October 21 at 4:00:00 PM EDT
$52.70
-0.50
(-0.94%)
Pre-Market:
4:22:14 AM EDT
DAY'S RANGE
$53.22
$52.90
$54.67
52-WEEK RANGE
$53.22
$26.76
$59.30
What's happening
- TGTX is down 2.41% today, trading at $53.22. — Live quote
- Volume today (48,310) is well below its 3-month average of 2,166,820. (Finnhub fundamentals)
- Reports earnings on 2026-11-09, 18 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $0.05 actual vs. $0.34 estimated (-85.5%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 3
Buy 9
Hold 1
Sell 1
Strong sell 0
Aggregate ratings for 2026-10-01 (14 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
TGTX
+82.93%
vs S&P 500
+70.15%
1-YEAR RETURN
TGTX
+55.27%
vs S&P 500
+40.71%
6-MONTH RETURN
TGTX
+58.98%
3-MONTH RETURN
TGTX
+1.08%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$0.05
Est. $0.34
MISS -85.5%
2026-04-26 (Q1 2026)
$0.18
Est. $0.30
MISS -40.1%
2026-01-26 (Q4 2025)
$0.14
Est. $0.36
MISS -60.9%
2025-10-26 (Q3 2025)
$0.16
Est. $0.22
MISS -28.7%
Valuation Measures & Ratios
Enterprise Value4$8.61B
Forward P/E526.42
PEG Ratio60.83
Price / Sales (TTM1)10.44
Price / Book713.92
EV4 / Revenue10.77
EV4 / EBITDA67.63
Profit Margin55.22%
Operating Margin15.91%
Return on Equity (ROE8)72.30%
Return on Assets (ROA9)33.59%
Avg Volume (3M)2,166,820
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $8.55B | $5.47B | $5.81B | $5.97B | $6.65B |
| P/E | 19.14 | 12.32 | 13.57 | 135.68 | 1300.47 |
| Price/Sales | 11.43 | 8.70 | 11.45 | 14.24 | 19.46 |
| Price/Book | 14.15 | 9.38 | 9.57 | 21.60 | 28.02 |
| EV/Revenue | 11.78 | 9.18 | 11.78 | 14.51 | 19.79 |
| EV/EBITDA | 72.95 | 53.61 | 70.10 | — | — |
| ROE | 73.94% | 76.13% | 70.49% | 15.92% | 2.15% |
| ROA | 27.24% | 29.04% | 41.76% | 6.26% | 0.78% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short30,634,421
Change from Prior Settlement+1.59%
% of Float—
Days to Cover (Short Ratio)15.03
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 70.3% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is 55.2%. Finnhub fundamentals ↗
- Trailing 52-week price return is +55.3%. Finnhub market metrics ↗
Potential concerns
- Latest SEC filing is Form 4, filed 2026-09-14; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on TGTX
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $240.3M | $204.9M | $161.7M | $141.1M | $120.9M | $83.9M | $73.5M | $63.5M |
| Operating income | $21.7M | $34.8M | $29.4M | $34.8M | $8.6M | $12.4M | $8.8M | -$9.3M |
| Net income | $7.8M | $19.8M | $390.9M | $28.2M | $5.1M | $3.9M | $6.9M | -$10.7M |
| EPS (diluted) | $0.05 | $0.12 | $2.43 | $0.17 | $0.03 | $0.02 | $0.04 | $-0.07 |
| EPS (basic) | $0.05 | $0.14 | $2.69 | $0.19 | $0.03 | $0.03 | $0.05 | $-0.07 |
| Operating margin | $9 | $17 | $18 | $25 | $7 | $15 | $12 | -$15 |
| Net margin | $3 | $10 | $242 | $20 | $4 | $5 | $9 | -$17 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $1.64B | $1.53B | $1.06B | $1.03B | $702.6M | $656.7M | $577.7M | $586.0M |
| Total liabilities | $1.04B | $945.7M | $415.2M | $417.8M | $426.2M | $419.4M | $355.3M | $393.9M |
| Stockholders' equity | $604.1M | $583.1M | $648.0M | $607.2M | $276.4M | $237.3M | $222.4M | $192.2M |
| Total current assets | $1.15B | $1.09B | $630.8M | $599.8M | $664.0M | $644.5M | $566.4M | $574.1M |
| Total current liabilities | $268.5M | $187.1M | $153.8M | $156.8M | $171.9M | $160.2M | $90.7M | $125.1M |
| Cash & equivalents | $482.6M | $442.2M | $79.1M | $74.1M | $129.1M | $132.1M | $179.9M | $195.8M |
| Marketable securities (current) | $69.7M | $72.2M | $62.8M | $57.5M | $122.7M | $144.1M | $131.1M | $145.2M |
| Accounts receivable | $401.6M | $392.0M | $305.6M | $265.4M | $231.5M | $190.1M | $129.2M | $115.7M |
| Inventory | $148.0M | $129.0M | $125.6M | $147.0M | $155.2M | $157.8M | $110.5M | $84.7M |
| Other current assets | $43.9M | $51.5M | $57.6M | $55.8M | $25.4M | $20.4M | $15.7M | $32.6M |
| Marketable securities (non-current) | $64.4M | $61.5M | $59.1M | $48.8M | $28.6M | $1.9M | $808.0K | $1.1M |
| Property, plant & equipment | — | — | — | — | — | — | — | — |
| Goodwill | — | — | — | — | — | — | — | — |
| Other non-current assets | $2.2M | $2.0M | $2.0M | $2.0M | $2.0M | $2.0M | $2.1M | $2.1M |
| Deferred revenue (current) | $16.8M | $17.2M | $21.2M | $26.4M | $23.9M | $17.1M | $11.4M | $9.1M |
| Short-term debt | — | — | — | — | — | — | — | — |
| Other current liabilities | $857.0K | $596.0K | $2.1M | $2.0M | $2.3M | $2.9M | $4.6M | $3.3M |
| Long-term debt | $745.4M | $745.1M | $245.6M | $245.3M | $245.0M | $244.7M | $244.4M | $244.2M |
| Other non-current liabilities | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $160.0K | $160.0K | $159.0K | $159.0K | $159.0K | $159.0K | $156.0K | $156.0K |
| Retained earnings | -$1.05B | -$1.06B | -$1.08B | -$1.11B | -$1.50B | -$1.52B | -$1.53B | -$1.55B |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $39.3M | -$17.9M | $19.7M | -$23.2M | $7.4M | -$28.7M | -$25.6M | -$12.2M |
| Investing cash flow | $1.0M | -$9.9M | -$15.6M | $46.4M | -$4.0M | -$12.9M | $15.8M | -$9.3M |
| Financing cash flow | $85.0K | $390.8M | $1.1M | -$78.2M | -$6.4M | -$6.1M | -$6.1M | $134.5M |
| Free cash flow | $39.0M | -$17.9M | $19.6M | -$23.2M | $7.4M | -$28.7M | -$25.7M | -$12.2M |
| Capital expenditures | $293.0K | $51.0K | $67.0K | $80.0K | $42.0K | $25.0K | $21.0K | $24.0K |
| Depreciation & amortization | $53.0K | $32.0K | $21.0K | $17.0K | $13.0K | $8.0K | $9.0K | $11.0K |
| Share-based compensation | $27.9M | $19.9M | $15.7M | $17.7M | $16.4M | $15.0M | $11.9M | $11.8M |
| Deferred income taxes | $708.0K | $3.9M | $18.6M | -$366.6M | $0 | $0 | $0 | $0 |
| Change in accounts receivable | $9.5M | $86.4M | $40.2M | $33.9M | $41.4M | $60.9M | $13.5M | $32.1M |
| Change in inventory | $66.8M | $13.3M | -$563.0K | -$8.7M | -$3.6M | $46.3M | $24.8M | $2.5M |
| Purchases of investments | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — |
| Debt repaid | — | — | — | — | — | — | — | — |
| Other financing activities | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $616.3M | $329.0M | $233.7M | $2.8M | $6.7M |
| Operating income | $123.3M | $41.9M | $20.6M | -$218.3M | -$344.8M |
| Net income | $447.2M | $23.4M | $12.7M | -$223.8M | -$348.1M |
| EPS (diluted) | $2.77 | $0.15 | $0.09 | $-1.65 | $-2.63 |
| EPS (basic) | $3.10 | $0.16 | $0.09 | $-1.65 | $-2.63 |
| Operating margin | $20 | $13 | $9 | -$7.8K | -$5.2K |
| Net margin | $73 | $7 | $5 | -$8.0K | -$5.2K |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $1.06B | $577.7M | $329.6M | $193.6M | $379.6M |
| Total liabilities | $415.2M | $355.3M | $169.1M | $135.0M | $142.5M |
| Stockholders' equity | $648.0M | $222.4M | $160.5M | $58.6M | $237.2M |
| Total current assets | $630.8M | $566.4M | $317.9M | $168.3M | $331.0M |
| Total current liabilities | $153.8M | $90.7M | $53.7M | $53.2M | $65.4M |
| Cash & equivalents | $79.1M | $179.9M | $92.9M | $102.3M | $298.9M |
| Marketable securities (current) | $62.8M | $131.1M | $124.6M | $59.4M | $15.9M |
| Accounts receivable | $305.6M | $129.2M | $51.1M | $0 | — |
| Inventory | $125.6M | $110.5M | $39.8M | $0 | — |
| Other current assets | $57.6M | $15.7M | $9.5M | $2.4M | $2.9M |
| Marketable securities (non-current) | $59.1M | $808.0K | $0 | $12.4M | $35.5M |
| Property, plant & equipment | — | — | $95.0K | $307.0K | $600.0K |
| Goodwill | — | — | $799.0K | $799.0K | $799.0K |
| Other non-current assets | $2.0M | $2.1M | $2.3M | — | — |
| Deferred revenue (current) | $21.2M | $11.4M | $152.0K | — | — |
| Short-term debt | — | — | — | $0 | $975.0K |
| Other current liabilities | $2.1M | $4.6M | $1.5M | $1.2M | $1.5M |
| Long-term debt | $245.6M | $244.4M | $100.1M | $71.1M | $66.8M |
| Other non-current liabilities | — | — | — | — | — |
| Common stock & paid-in capital | $159.0K | $156.0K | $151.0K | $146.0K | $143.0K |
| Retained earnings | -$1.08B | -$1.53B | -$1.55B | -$1.53B | -$1.33B |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$24.8M | -$40.5M | -$31.4M | -$176.2M | -$295.6M |
| Investing cash flow | $13.8M | -$1.0M | -$50.7M | -$20.0M | -$332.0K |
| Financing cash flow | -$89.7M | $128.5M | $72.7M | -$391.0K | $41.4M |
| Free cash flow | -$25.0M | -$40.6M | -$31.4M | -$176.2M | -$296.0M |
| Capital expenditures | $214.0K | $45.0K | $0 | $14.0K | $401.0K |
| Depreciation & amortization | $59.0K | $68.0K | $211.0K | $303.0K | $282.0K |
| Share-based compensation | $64.7M | $42.5M | $37.9M | $44.7M | $61.3M |
| Deferred income taxes | -$348.0M | $0 | $0 | — | — |
| Change in accounts receivable | $176.4M | $78.1M | $51.1M | -$1.4M | $1.4M |
| Change in inventory | $33.5M | $66.9M | $36.9M | $0 | $0 |
| Share repurchases | — | — | — | — | — |
| Debt repaid | — | — | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding TGTX as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Insider activity is not available for this symbol right now.
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 09:14 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-14 | 4 | 2026-09-10 | View on SEC.gov → |
| 2026-08-07 | 4 | 2026-08-06 | View on SEC.gov → |
| 2026-08-05 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-03 | 8-K | 2026-08-03 | View on SEC.gov → |
| 2026-06-15 | 4 | 2026-06-11 | View on SEC.gov → |
| 2026-06-15 | 4 | 2026-06-11 | View on SEC.gov → |
| 2026-06-15 | 4 | 2026-06-11 | View on SEC.gov → |
| 2026-06-15 | 4 | 2026-06-11 | View on SEC.gov → |
| 2026-06-15 | 4 | 2026-06-11 | View on SEC.gov → |
| 2026-06-12 | 8-K | 2026-06-11 | View on SEC.gov → |
| 2026-06-03 | 8-K | 2026-06-03 | View on SEC.gov → |
| 2026-05-27 | 8-K | 2026-05-27 | View on SEC.gov → |
Recent news
Headlines about TGTX (TG Therapeutics, Inc.). Links open the publisher — we don’t host full articles.
-
TG Therapeutics, Inc. (TGTX) Stock Forecasts
Yahoo Finance · 2026-10-21 -
TG Therapeutics (TGTX) Showcases Long-Term MS Trial Data and Adv
GuruFocus · 2026-10-21 -
TG Therapeutics reports seven-year BRIUMVI disability and safety findings
Mugglehead Investment Magazine · 2026-10-21 -
TG Therapeutics Highlights New Clinical Data Across Multiple Sclerosis Portfolio at MSToronto2026
Yahoo · 2026-10-21 -
Labcorp Prepares to Report Q3 Earnings: What's in the Cards?
Yahoo · 2026-10-21 -
TGTX Nov 2026 22.000 put (TGTX261120P00022000) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-19 -
TGTX Jun 2028 70.000 put (TGTX280616P00070000) interactive stock chart
Yahoo Finance UK · 2026-10-19 -
TGTX May 2027 50.000 put (TGTX270521P00050000) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-19
No headlines in this category right now — try “All”.